Consistent with ALK-fusion NSCLC patients and with the previous studies, we found pemetrexed-based chemotherapy showed a better effect in ROS1 fusion-positive patients than non-pemetrexed-based chemotherapy [14–16, 29, 30]. This evidence concerns the gene ALK and non-small cell lung carcinoma.